Mark R Bray, PhD

Dr. Bray has over 20 years of experience in drug discovery, preclinical drug development and research project management in environments ranging from entrepreneurial start-ups to large biotech. His background and interests lie in cancer research with a focus towards development of novel therapeutics for cancer and inflammatory diseases.

Since 2012, Dr. Bray has directed all activities of the multi-disciplinary drug discovery and development team at UHN's Campbell Family Institute for Breast Cancer Research (CFIBCR). Under his leadership, multiple drug programs have been progressed from discovery to clinical trials including ENMD-2076, CFI-400945, and CFI-402257. The extensive portfolio of clinical and early stage assets developed by CFIBCR are now being spun out into multiple ventures including Toricon Therapeutics, where Dr. Bray is a Founder and Chief Scientific Officer.

Dr. Bray originally came to the Ontario Cancer Institute, Princess Margaret Hospital in 1996 as a postdoctoral fellow, where he invented combinatorial protein library technology that formed the basis of UHN spinout biotech company Molecular Templates, Inc. Next, he joined the Amgen Research Institute (ARI) in 1999, and until 2002 acted as scientific liaison between the UHN-based ARI and Amgen, Thousand Oaks CA, responsible for identifying, initiating and leading early stage discovery programs into therapeutic development. After Amgen negotiated out of its contract with the UHN in 2002, Dr. Bray co-founded the biotech startup Miikana Therapeutics along with Tak W. Mak and Gail Eckhardt, and was Director of Research until Miikana was acquired in 2006 by Rockville, MD based EntreMed, Inc (now CASI Pharmaceuticals). Dr. Bray was Vice President, Research for EntreMed/CASI, from 2007 - 2012 before leaving his position to lead the CFIBCR Therapeutics Team.

Br J Cancer. 2019 Jul 15;:
Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, Sampson P, Li SW, Pugh TJ, Bruce J, Bray MR, Slamon DJ, Mak TW, Wainberg ZA, Bedard PL
Nat Commun. 2019 06 18;10(1):2678
Kubli SP, Vornholz L, Duncan G, Zhou W, Ramachandran P, Fortin J, Cox M, Han S, Nechanitzky R, Nechanitzky D, Snow BE, Jones L, Li WY, Haight J, Wakeham A, Bray MR, Mak TW
J Neurosci. 2018 Aug 15;38(33):7201-7203
Boulos ME, Bray MJC
Oncogene. 2017 Nov 16;36(46):6501-6507
Szymiczek A, Carbone M, Pastorino S, Napolitano A, Tanji M, Minaai M, Pagano I, Mason JM, Pass HI, Bray MR, Mak TW, Yang H
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132
Mason JM, Wei X, Fletcher GC, Kiarash R, Brokx R, Hodgson R, Beletskaya I, Bray MR, Mak TW
Oncotarget. 2017 Jan 10;8(2):3064-3071
Lohse I, Mason J, Cao PM, Pintilie M, Bray M, Hedley DW
ACS Med Chem Lett. 2016 Jul 14;7(7):671-5
Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Plotnikova O, Awrey DE, Qiu W, Chirgadze NY, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Fletcher GC, Mak TW, Bray MR, Pauls HW
Invest New Drugs. 2016 10;34(5):614-24
Yee KW, Chen HW, Hedley DW, Chow S, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Sanfelice D, Johnson T, Le LW, Arnott J, Bray MR, Sidor C, Minden MD
Bioorg Med Chem Lett. 2016 08 01;26(15):3562-6
Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW
Mol Cell. 2015 Nov 19;60(4):524-36
Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR, Mak TW


Director, Campbell Family Institute Therapeutics Group